NCT06111547View on ClinicalTrials.gov

A Study of TAK-279 in Healthy Chinese Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 24, 2024

Primary Completion Date

July 23, 2024

Study Completion Date

August 4, 2024

Conditions
Healthy Volunteers
Interventions
DRUG

TAK-279

TAK-279 oral tablet.

DRUG

Placebo

TAK-279 30 mg or 60 mg (2\*30mg) matching placebo tablet.

Trial Locations (1)

201100

Huashan Hospital Fudan University, Shanghai

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY